Video: New GLP-1 FDA Warning: NAION & Medical Malpractice Lawsuits
November 12, 2026
Transcript
GLP-1 Vision Loss and Medical Malpractice Lawsuits: FDA Warnings, NAION, Ozempic, and Wegovy
Now that the FDA has announced a warning about potential permanent vision loss from GLP-1 medications, could doctors face medical malpractice lawsuits for continuing to prescribe them?
The answer is yes, potentially, but not simply because they prescribe the medication.
I’m Attorney Tracy Paulsen, founder of Rightful Legal.
FDA Guidance on NAION and Vision Changes From GLP-1 Medications
The FDA has now specifically advised healthcare professionals to recognize the potential risk of NAION and to instruct patients to report sudden vision changes and promptly refer patients to an ophthalmologist when NAION is suspected.
When Should Doctors Reassess GLP-1 Medication?
The agency also recommends considering discontinuation of this medication if NAION develops, unless the treatment’s benefits clearly outweigh the risks.
So what does that mean for physicians going forward?
Ozempic and Wegovy: A Potential Medical Malpractice Scenario
Consider a patient who is prescribed Ozempic or Wegovy, and the patient later develops sudden vision changes and reports those symptoms to the doctor.
The patient is told not to worry about it, and there is no urgent evaluation, no referral, and no meaningful reassessment of the medication.
Then the patient subsequently suffers further vision loss and is diagnosed with NAION after taking GLP-1 medications.
That could raise serious medical malpractice questions.
When Could Physician Liability Arise From GLP-1 Vision Loss?
The legal issue would be whether the physician failed to meet the applicable standard of care and whether that failure actually caused preventable harm.
Informed Consent and GLP-1 Medication Risks
There’s also the issue of informed consent.
As this warning becomes part of prescribing guidance, physicians will need to consider how to communicate this potential risk so patients can make informed treatment decisions.
Does the FDA Warning Mean Patients Should Stop Taking GLP-1 Medications?
A new FDA warning does not automatically establish malpractice or require every patient to stop taking these medications.
But it does create important new information that physicians cannot simply ignore.
And how doctors respond to that information could become central to future medical malpractice litigation.
Vision Loss After GLP-1 Medication: Potential Legal Options
If you’ve experienced vision loss and were diagnosed with NAION after taking a GLP-1 medication, I’d be more than happy to speak with you about your story and your possible legal pathways to justice and compensation.
This is our goal: to protect the community and make sure that everybody knows about these inherent risks when pharmaceutical companies put profits ahead of people.
Contact Attorney Tracy Paulsen at Rightful Legal
You can reach me directly at 617-821-5856, or you can find us at rightfullegal.com and schedule a consultation online.
Thank you so much.


